LAIR-1 agonism as a therapy for acute myeloid leukemia

Rustin R. Lovewell,Junshik Hong,Subhadip Kundu, Carly M. Fielder,Qianni Hu,Kwang Woon Kim,Haley E. Ramsey,Agnieszka E. Gorska,Londa S. Fuller,Linjie Tian, Priyanka Kothari,Ana Paucarmayta,Emily F. Mason, Ingrid Meza, Yanira Manzanarez,Jason Bosiacki,Karla Maloveste, Ngan Mitchell, Emilia A. Barbu,Aaron Morawski, Sebastien Maloveste, Zac Cusumano,Shashank J. Patel,Michael R. Savona,Solomon Langermann,Han Myint,Dallas B. Flies,Tae Kon Kim

JOURNAL OF CLINICAL INVESTIGATION（2023）

引用 0|浏览6

暂无评分

摘要

Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remains unexplored. We developed a therapeutic LAIR-1 agonist antibody, NC525, that induced cell death of LSCs, but not We showed that LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells that was enhanced in the presence of collagen. NC525 also significantly improved the activity of azacitidine and venetoclax to establish LAIR-1 targeting as a therapeutic strategy for AML that may synergize with standard-of-care therapies.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要